Eone Diagnomics Genome Center Balance Sheet Health
Financial Health criteria checks 2/6
Eone Diagnomics Genome Center has a total shareholder equity of ₩72.4B and total debt of ₩55.6B, which brings its debt-to-equity ratio to 76.8%. Its total assets and total liabilities are ₩164.1B and ₩91.7B respectively.
Key information
76.8%
Debt to equity ratio
₩55.59b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩10.23b |
| Equity | ₩72.38b |
| Total liabilities | ₩91.72b |
| Total assets | ₩164.09b |
Recent financial health updates
Is Eone Diagnomics Genome Center (KOSDAQ:245620) Weighed On By Its Debt Load?
Apr 06
Eone Diagnomics Genome Center (KOSDAQ:245620) Is Carrying A Fair Bit Of Debt
Dec 16Recent updates
There's No Escaping Eone Diagnomics Genome Center Co., Ltd.'s (KOSDAQ:245620) Muted Revenues Despite A 43% Share Price Rise
Feb 29Is Eone Diagnomics Genome Center (KOSDAQ:245620) Weighed On By Its Debt Load?
Apr 06If You Had Bought Eone Diagnomics Genome Center (KOSDAQ:245620) Shares A Year Ago You'd Have Earned 54% Returns
Feb 24Do Insiders Own Lots Of Shares In Eone Diagnomics Genome Center Co., Ltd. (KOSDAQ:245620)?
Jan 20Eone Diagnomics Genome Center (KOSDAQ:245620) Is Carrying A Fair Bit Of Debt
Dec 16Financial Position Analysis
Short Term Liabilities: A245620's short term assets (₩38.3B) do not cover its short term liabilities (₩45.0B).
Long Term Liabilities: A245620's short term assets (₩38.3B) do not cover its long term liabilities (₩46.7B).
Debt to Equity History and Analysis
Debt Level: A245620's net debt to equity ratio (62.7%) is considered high.
Reducing Debt: A245620's debt to equity ratio has increased from 10.8% to 76.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A245620 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A245620 is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/07/03 04:14 |
| End of Day Share Price | 2024/04/05 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Eone Diagnomics Genome Center Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tal Mi Lee | SK Securities Co., Ltd. |